Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Adenocarcinoma of the pancreas. General characteristics].
André T, Balosso J, Louvet C, Gligorov J, Callard P, de Gramont A, Izrael V. André T, et al. Among authors: izrael v. Presse Med. 1998 Mar 21;27(11):533-6. Presse Med. 1998. PMID: 9767968 Review. French.
[Adenocarcinoma of the pancreas. Diagnosis and evaluation].
André T, Balosso J, Louvet C, Gligorov J, Couteau C, Avenin D, de Gramont A, Izrael V. André T, et al. Among authors: izrael v. Presse Med. 1998 Mar 21;27(11):537-8. Presse Med. 1998. PMID: 9767969 French.
[Adenocarcinoma of the pancreas. Therapeutic strategies].
André T, Balosso J, Louvet C, Houry S, Vaillant JC, Touboul E, Lotz JP, de Gramont A, Izrael V. André T, et al. Among authors: izrael v. Presse Med. 1998 Mar 21;27(11):539-45. Presse Med. 1998. PMID: 9767970 Review. French.
Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study.
André T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, Colonna M, Lotz JP, De Gramont A, Bellaïche A, Parc R, Touboul E, Izrael V. André T, et al. Among authors: izrael v. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):903-11. doi: 10.1016/s0360-3016(99)00478-2. Int J Radiat Oncol Biol Phys. 2000. PMID: 10705012
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.
Maindrault-Goebel F, Louvet C, André T, Carola E, Lotz JP, Molitor JL, Garcia ML, Gilles-Amar V, Izrael V, Krulik M, de Gramont A. Maindrault-Goebel F, et al. Among authors: izrael v. Eur J Cancer. 1999 Sep;35(9):1338-42. doi: 10.1016/s0959-8049(99)00149-5. Eur J Cancer. 1999. PMID: 10658524 Clinical Trial.
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A. André T, et al. Among authors: izrael v. Eur J Cancer. 1999 Sep;35(9):1343-7. doi: 10.1016/s0959-8049(99)00150-1. Eur J Cancer. 1999. PMID: 10658525 Clinical Trial.
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M; Oncology Multidisciplinary Research Group (GERCOR). Maindrault-Goebel F, et al. Among authors: izrael v. Eur J Cancer. 2001 May;37(8):1000-5. doi: 10.1016/s0959-8049(01)00068-5. Eur J Cancer. 2001. PMID: 11334725 Clinical Trial.
56 results